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ABSTRACT 
 
This study aims to establish the clinicopathological characteristics of patients with melanoma and their 
association with BRAF gene mutations. Pathology reports and paraffin-embedded tumor samples from 
47 ´¡ women and 30 men with melanoma and an average age of diagnosis of 60 were examined at the 
Hospital Federico Lleras Acosta in Ibague, between 2010 and 2016. The presence of V600E mutation 
at BRAF exon 15 was analyzed in these tumoral samples by Sanger sequencing and visual inspection of 
electropherograms. Clinicopathological variables were also studied using X2, t-Student and the Kaplan 
Meier index. Most of the lesions were located in the lower limbs (46.6 %). The most frequent subtype 
was acral lentiginous melanoma (41.8 %). Most lesions were of poor prognosis: Breslow depth greater 
than 4.1 mm (52.7 %), ulceration (61.4 %) and medium or high mitotic rate (> 30 %). V600E mutation 
was identified in five patients with large, deep and ulcerated tumors, four of whom had less than four 
years of survival. In conclusion, melanoma is highly frequent in women, V600E BRAF mutation is 
present in patients with advanced disease (high Breslow index), and the five-year survival rate is less 
than 40 %. 
RESUMEN 
 
El objetivo de este estudio fue establecer las características clínico-patológicas de los pacientes con 
melanoma y su asociación con mutaciones del gen BRAF. Los informes de patología y las muestras de 
tumores incluidos en parafina de 47 mujeres y 30 hombres con melanoma, con una edad promedio de 
diagnóstico de 60 años, se revisaron en el Hospital Federico Lleras Acosta de Ibagué, entre 2010 y 2016. 
En estos tejidos tumorales se detectó la presencia de la mutación V600E del exón 15 del gen BRAF, 
mediante secuenciación por el método de Sanger e inspección visual del electroferograma. Además, 
se estudiaron las variables clínico-patológicas con X2, t-Student e índice Kaplan Meier. La mayoría de 
las lesiones estaban localizadas en las extremidades inferiores (46,6 %). El subtipo más frecuente fue 
el melanoma lentiginoso acral (41,8 %). La mayoría eran de mal pronóstico: profundidad superior a 4,1 
mm (52,7 %), ulceración (61,4 %) y tasa mitótica media o alta (> 30 %). La mutación V600E se identificó 
en cinco pacientes con tumores grandes, profundos y ulcerados, cuatro de ellos tuvieron una 
supervivencia menor de cuatro años. En conclusión, hubo mayor frecuencia de melanoma en mujeres, 
la mutación V600E BRAF se presentó en pacientes con enfermedad avanzada y la probabilidad de 
supervivencia a cinco años fue inferior al 40 %. 
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INTRODUCTION 
 
Melanoma is a tumor of aggressive behavior that 
develops in melanocytic cells, mainly the skin, 
although it may also appear in the eye and various 
mucosal surfaces1,2. It is a rare and heterogeneous 
form of cancer with a complex multigenic etiology3,4. 
Its high degree of malignancy and high tendency to 
metastasize result in an unfavorable prognosis, 
since the overall five-year survival rate for patients 
with more than three metastases to lymph nodes or 
distant organs is less than 16 %, representing 90 % 
of deaths associated with skin tumors5-7. 
Interestingly, in Colombian studies, the overall 
melanoma-specific five-year survival rate is 
substantially lower than that reported by countries 
with higher incidence8.  
 
According to its clinical and histopathological 
characteristics, melanoma is classified into four 
subtypes: superficial spreading melanoma, 
generally flat and irregular in shape and color; 
nodular melanoma, of a brown-black color, 
characterized by an aggressive vertical growth 
phase; lentigo maligna melanoma, which appears 
mainly in the elderly on skin exposed to the sun 
(face, neck and arms), described as a lentiginous 
proliferation of atypical melanocytes; and finally, 
the rare acral lentiginous melanoma, which occurs 
mainly on the palms of the hands and the soles of 
the feet and, during the initial intraepidermal phase, 
has irregular pigmentation and may later exhibit a 
nodular formation with invasive growth4,9,10. 
 
In 2017, the American Cancer Society reported 
about 87,100 new cases of melanoma with a 
mortality of 9,730 in the United States5,11. In general, 
the incidence rate has been increasing around the 
world, especially in people with white skin who have 
higher exposure to the sun9,12. The incidence rate of 
new cases of melanoma per 100,000 inhabitants is 
10-25 in Europe, 20-30 in the United States, and 50-
60 in Australia1,11,13-15. 
 
Since Colombia does not have a unique cancer 
registry system and only some reports on its 
estimated incidence are known16, it is difficult to 
establish general data on the affected population. In 
2012, GLOBOCAN reported an incidence of 
melanoma of 2.3 and 1.9 for men and women, 
respectively, and a mortality rate of 0.9 %, 
evidencing a decrease compared to 1.3 % reported 
in 2010 by the National Institute of Cancerology, 
which can be attributed to early diagnosis and 
prevention campaigns16. 
 
In this sense, it is essential to implement methods 
that pinpoint the prognostic factors of the disease, 
including the Breslow classification, which helps 
determine the extent of melanoma and is 
considered one of the most important 
clinicopathological features when predicting the 
survival time of patients with melanoma5. According 
to Classic Pathology, the chances of a patient being 
treated and cured in early stages of the disease are 
high, compared with those of a person in an 
advanced state that has low probability of survival. 
The authors conclude that patients with tumors 
larger than two millimeters thick are at risk of 
developing loco-regional cutaneous metastases17. 
 
The progress of molecular studies has shown that 
solar ultraviolet (UV) radiation is an important 
environmental risk factor for the development of 
melanoma3,13,15,18. It has been shown that the risk 
varies depending on geographical location, type of 
skin, hair color, number of nevi and family history of 
melanoma3,18,19 .  
 
The growing incidence of melanoma worldwide has 
stimulated an increase in research aimed at 
identifying the genetic, environmental and 
phenotypic factors that contribute to its 
pathogenicity3,12. Recent studies have shown that 
between 40 and 60 % of cases show somatic 
mutations in the BRAF gene, with the V600E 
mutation being the most frequent (50 %) in patients 
with metastatic melanoma20 and usually has a 
spindle cell morphology21. 
 
This study analyzes the clinicopathological factors in 
patients with melanoma, as well as the 
characteristics of the tumor and survival using the 
Kaplan Meier index. In addition, BRAF exon 15 was 
sequenced to establish the presence of somatic 
mutations in the DNA obtained from paraffin-
embedded tumor tissues. 
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MATERIALS AND METHODS 
 
Population, sample and type of study  
 
This study is part of the program “Genetic Analysis 
of Human Diseases” developed by the Cytogenetics, 
Phylogeny and Evolution of Populations research 
group of the Universidad del Tolima since 2005, 
which was approved by the University’s Bioethics 
Committee and the Hospital Federico Lleras Acosta 
(HFLLA). We reviewed 77 pathologies of patients 
diagnosed with melanoma during the 2010-2016 
period. Records were anonymized and 
epidemiological (age of diagnosis, gender, and year 
of death), clinical (location and histological type) and 
pathological (ulceration, Breslow index, and mitotic 
rate) variables analyzed. 
 
Instruments and procedures 
 
Tissue embedded in paraffin was obtained from 56 
patients residing in Ibague, Tolima. A pathologist 
(MEB) demarcated tumor regions with > 80 % of 
tumor cells on H&E slides and, from them, total DNA 
extraction was performed by the silica microcolumn 
extraction protocol (QIAGEN KIT, Dneasy - Blood & 
Tissue Kit, Cat. N° 69504), following the 
manufacturer’s recommendations.  
 
Amplification of BRAF exon 15 was performed using 
conventional PCR with forward (5’-
AGAAATTAGATCTCTTACCTAAACT-3’) and reverse 
(5’-TTACCATCCACAAAATGGA-3’) primers. As a 
positive control, DNA extracted from a positive 
thyroid cancer patient was used for the BRAF V600E 
mutation and, as a negative control, ultra-pure 
water was used instead of DNA. Each mixture was 
brought to a final volume of 25 μl. The thermal 
profile consisted of an initial denaturation at 95 °C 
for 5 minutes, followed by 35 cycles of denaturation, 
alignment and extension at 95 °C (1 minute), 55 °C 
(1 minute) and 72 °C (1 minute), and a final 
extension at 71 °C for 10 minutes.  
 
Amplified products were visualized by agarose gel 
electrophoresis and sequenced by Sanger at 
Macrogen (Korea). Sequences were aligned using 
BLAT in the UCSC Genome Browser 
(https://genome.ucsc.edu/cgi-
bin/hgBlat?command=start) with human genome 
version GRCh38/hg38. Mutation status in BRAF 
(V600E) was visually inspected in 
electropherograms with 4Peaks v. 1.7 by two 
experienced independent researchers (CJP, MEB). 
Mutation calling concordance was 100 %. 
 
Statistical analysis  
 
For the statistical analysis, VassarStats algorithms 
were used to calculate the X2 and t-Student tests 
and R version 1.68 for the Kaplan Meier test. 
Variables were described in frequencies or means 
and standard deviations. 
 
Data were compared with information from global 
(The Cancer Genome Atlas Program -TCGA) and local 
databases, for clinic and histological characteristics, 
as Breslow index, including ulceration and 
histological type, so as reported mutations and 
survival rates. 
 
Ethical considerations 
 
To guarantee compliance with the principles and 
ethical standards of the Declaration of Helsinki of 
1975, as amended, and Resolution 8430 of 1993 by 
the Colombian Ministry of Health, and after 
authorization of the research program, a search was 
made in the database and the clinical history of 
patients, and data, as well as paraffin blocks and 
histology slides, were tabulated in a randomized 
manner and totally anonymized. 
 
RESULTS 
 
Clinicopathological data are summarized in Table 1. 
A total of 77 patients (47 women and 30 men) from 
the city of Ibague with a diagnosis of melanoma 
confirmed by histopathology were included. No 
significant differences were found in the average 
age of diagnosis between genders (t = 1.03, df = 75, 
P = 0.306), being 59.54 ± 6.8 years for men and 60.12 
± 5.12 years for women. It is highlighted that 57 % of 
people were diagnosed before age 60. Annual 
distribution of cases was 17 in 2010, 19 in 2011, 18 
in 2012, 13 in 2013, 3 in 2014, 5 in 2015, and 2 in 
2016. 
The anatomical locations were, in order of 
importance, lower limbs (48.8 % in women and 
43.3 % in men), head and neck, and upper limbs 
(Table 1). In 41.8 % of the cases there was acral 
melanoma (17 women and 11 men), affecting the 
soles of the feet, nails and palms, followed by 
atypical melanocytic lesions with 22.4 % (Table 1). D
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The depth of tumors, measured according to the 
Breslow index, showed that 52.7 % (29 of 55 cases) 
had a lesion deeper than 4 mm and in 47.3 % (26 
people) it was less than or equal to 4 mm; 22 
pathology reports were missing the Breslow index 
(Table 1 and Figure 1).  
 
 
 
 
Figure 1. Depth of lesion (Breslow) according to gender and age of diagnosis. 
 
Ulceration occurred in 61.4 % (35 people) and was 
more evident at a higher age of diagnosis. It is 
noteworthy that this was the only variable with 
significant differences between genders (p = 0.042), 
being more frequent in men (81 %) than in women 
(50 %) (Table 1 and Figure 2).   
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Table 1. Clinicopathological Characteristics of Patients Included in the Sample. 
 
Variable Women  n (%) Men n (%) Total n (%) P Value 
Age 
≤ 60 29 (61.7) 15 (50) 44 (57.1) 
0.4386 
> 60 18 (38.3) 15 (50) 33 (42.9) 
Average 60.1 59.5 59.9  
Biopsy or resection 
Biopsy 23 (52.3) 11 (44) 34 (49.3) 
0.6801 
Resection 21 (47.7) 14 (56) 35 (50.7) 
Not reported 3 5 8  
Anatomical 
location 
Head and neck 9 (20.9) 4 (13.3) 13 (17.8) 
0.292 
Lower limbs 21 (48.8) 13 (43.3) 34 (46.6) 
Upper limbs 6 (14) 4 (13.3) 10 (13.7) 
Trunk 5 (11.6) 4 (13.3) 9 (12.3) 
Other 2 (4.7) 5 (16.7) 7 (9.6) 
Not reported 4  4  
Histological type 
Acral lentiginous 17 (40.5) 11 (44) 28 (41.8) 
0.2977 
Lentigo maligna 7 (16.7) 1 (4) 8 (11.9) 
Atypical melanocytic lesion 7 (16.7) 8 (32) 15 (22.4) 
Superficial spreading melanoma 3 (7.1) 0 3 (4.5) 
Nodular 8 (19) 5 (20) 13 (19.4) 
Not reported 5 5 10  
Diameter 
≤ 20 23 (50) 13 (48.1) 36 (49.3) 
0.9203 
> 20 23 (50) 14 (51.9) 37 (50.7) 
Not reported 1 3 4  
Depth (Breslow) 
≤ 4 mm 18 (51.4) 8 (40) 26 (47.3) 
0.5902 
> 4 mm 17 (48.6) 12 (60) 29 (52.7) 
Not reported 12 10 22  
Ulceration 
No 18 (50) 4 (19) 22 (38.6) 
0.0419 
Yes 18 (50) 17 (81) 35 (61.4) 
Not reported 11 9 20  
Mitotic rate 
Low 12 (34.3) 7 (29.2) 19 (32.2) 
0.2516 Moderate 15 (42.9) 6 (25) 21 (35.6) 
High 8 (22.9) 11 (45.8) 19 (32.2) 
Not reported 12 6 18  
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Figure 2. Presence of ulceration according to gender and age of diagnosis. 
 
The mitotic rate did not show significant differences 
between genders and age of diagnosis (Table 1 and 
Figure 3), although it tends to be higher in patients 
with nodular melanoma, atypical melanocytic 
lesion, and acral lentiginous melanoma (Figure. 4).  
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 Figure 3. Mitotic rate according to gender and age of diagnosis. 
 
 
Figure 4. Characteristics of the tumor by histological type. 
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In relation to survival, 46 patients (59 %) died. From 
the year of diagnosis to death, a Kaplan Meier test 
was performed, which revealed that the survival of 
patients drastically decreased to less than 50 % from 
the second year after diagnosis and the probability 
of surviving four years or more was lower than 40 % 
(Figure 5). 
 
Figure 5. Kaplan Meier Survival Test. 
 
From the 77 pathologies, 56 paraffin-embedded 
tumor tissues were donated but only 41 tumors had 
regions with > 80 % of tumor cells on H&E slides for 
DNA extraction. However, due to the variation of 
the fixation methods used and the diverse types of 
paraffin embedding, the DNA extracted had low 
concentration and was highly fragmented. BRAF 
exon 15 was efficiently amplified and sequenced in 
24 of the cases, obtaining electropherograms with 
clearly differentiable peaks in 11 of them.  
 
Difficulties in DNA extraction, amplification and 
sequencing from paraffin-embedded tumors, and 
specifically from melanomas, has been reported 
previously. This can be explained by DNA 
fragmentation and degradation due to treatment 
with alcohols and formaldehyde, which is carried 
out for fixation in paraffin blocks, and exposure to 
high temperatures when inadequate paraffin is used 
for the process. In addition, the high concentration 
of melanin present in the skin, and even more so in 
melanomas, is a possible inhibitor of PCR, since 
melanin can bind and inactivate at least a portion of 
the DNA to be amplified, limiting the binding of DNA 
polymerase and affecting both the amplification and 
speed of extension thereof22,23. 
 
Five of the 11 correctly sequenced samples were 
V600E positives (Table 2). Four of these cases were 
men, and three of them died from the disease (in 
developing countries, patient follow-up is poor, so 
we have not exact data about the disease stage at 
the time of death) before reaching four years after 
diagnosis. The survivor was diagnosed at 22 years of 
age, with melanoma having epidural metastasis in 
2012. The only woman with the mutation was 
diagnosed at 49 years with a 65 mm tumor (depth of 
50 mm) and a survival of less than four years. All 
cases positive for V600E showed ulceration, except 
in a patient older than 80 years with an atypical 
melanocytic lesion.  
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Table 2. Clinicopathological Data of Ibague Population vs. TCGA Data.  
CLINICOPATHOLOGICAL DATA NUMBER OF PATIENTS 
P value 
A. Patient Clinical Information 
Colombia 
n = 77 
TGCA 
n = 333 
Age (at diagnosis), in years    
Mean 59.9 56.5 
0.136631 Median 57 57.0 
Range 10 to 98 15 to 90 
Gender    
Male n (%) 30 (39.0) 182 (62.0) 
0.00042 
Female n (%) 47 (61.0) 111 (38.0) 
B. Features of Initial Melanoma Diagnosis 
Known primary melanoma tumor    
Yes 56 (100) 262 (90.0) 
0.02752 
No 0 29 (10.0) 
Location of primary melanoma    
Head/Neck 13 (16.9) 25 (8.7) 0.059 
Trunk 9 (11.7) 106 (36.8) 0.00004 
Extremities 44 (57.1) 120 (41.6) 0.021 
Other 7 (9.1) 8 (2.8) 0.031 
Unknown 4 (5.2) 29 (10.1) 0.270 
Primary tumor ulceration at diagnosis    
Yes 35 (61.4) 99 (49.5) 0.638 
No 22 (38.6) 101 (50.5) 0.001 
Not reported 20 . . 
C. Mutation Status 
BRAF status n = 11 n = 289  
BRAF + wild type 6 (54.5) 154 (53.3) 
1.0 
BRAF + V600E 5 (45.5) 122 (42.2) 
 
 
DISCUSSION 
 
Melanoma is a public health problem; its incidence 
and mortality have increased mainly in European 
countries, the United States and Australia1,9,15. In 
Latin American countries such as Colombia, there 
are few reports published for this pathology16,24.  
 
This study reveals that it is more frequently 
diagnosed in women than in men, according to 
pathological anatomy reports. However, this 
difference seems to decrease with age, which agrees 
with studies conducted in the United States, England 
and some Nordic countries, as well as those 
reported by the National Cancer Institute of 
Colombia15,16. 
 
Based on some reports, women between 15 and 49 
years of age have the highest melanoma rates, but 
men over 50 are more likely to develop the disease. 
It is possible that in the case of women, they may be 
more intermittently exposed to the sun and UV rays; D
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there are multiple studies showing that BRAF 
mutations are most commonly developed in this 
type of exposure25. In the case of older men, they do 
not usually use sunscreen, hats or clothing that 
protect them from UV exposure; therefore, they are 
exposed for longer periods of time throughout their 
life26,27. Other studies have indicated that 
differences in the physiology of men and women 
play an important role in the development of 
melanoma; the skin of the man is thicker, secretes 
more sebum and has less subcutaneous fat, while 
that of women tends to repair more quickly the 
damage induced by UV radiation, as revealed by a 
Dutch study whose data show that the doses to elicit 
an immunosuppression response were three times 
lower in men than in women15. 
 
The results of this study show that the most 
frequent histological subtype corresponds to 
lentiginous acral melanoma (41.8 %), congruent 
with that reported by the INC for Colombia16, De 
Vries et al.24 in 2017 for Cali and Sheen et al. in 2017 
for Asian populations28. In contrast, in Caucasian 
populations there seems to be higher frequency of 
the superficial spreading melanoma17 subtype 
(63.2 %), followed by the nodular subtype 
(50.4 %)16,24,28,29. Differences between frequencies 
of melanoma subtypes in Colombia, with respect to 
Caucasian populations, can be attributed to the 
ethnic origin of each population and miscegenation. 
 
Regarding the anatomical location of lesions, both 
men and women exhibit melanoma more frequently 
in the lower limbs, head and neck, respectively. It 
has been reported that in British population men 
seem to develop detected melanoma in the trunk 
and women in the lower limbs18.  
 
The Breslow index is regularly used as a predictor of 
survival of patients diagnosed with melanoma and 
has been shown to be one of the most important 
clinicopathological characteristics5. According to 
this index, patients diagnosed with thin melanomas 
(less than 2 mm thick) in early stages have a lower 
risk of loco-regional cutaneous metastases and, in 
general, a good prognosis5,11. Meanwhile, the 
prognosis of cure for patients with melanoma of 
more than 2.1 mm thick is limited and the 
probability of five-year survival after diagnosis is 
unfavorable5. In this study, greater frequency was 
observed in the Breslow thickness (> 4.1 mm) and it 
can be deduced that these patients are associated 
with poor prognosis and higher mortality1,13. This 
may be due to late consultation and difficulties in 
accessing the health system in our country. Patients 
diagnosed with malignant melanoma and a tumor 
depth of more than 2 mm are at high risk of 
developing metastases5. It has been reported that in 
elderly patients, this characteristic is linked to 
cerebral metastasis and lower survival20,30. 
 
Ulceration is another adverse prognostic factor 
related to the tumor, mainly if it is deeper than 3 
mm. This results in a survival rate of approximately 
50 % at 10 years in relation to a 78 % if there is no 
presence of ulceration27. The depth or increasing 
Breslow index is usually accompanied by a high 
probability of coming into contact with the 
lymphatic vessels and is evidence of rapid tumor 
growth5. 
 
Of the 11 patients with sequenced BRAF exon 15 in 
the DNA of paraffin-embedded tissue, five had the 
V600E mutation of the BRAF gene. These patients 
had advanced disease and died early. In addition, 
one of the patients was diagnosed before age 30, 
which is consistent with that reported by Thomas et 
al., who describe a significant association between 
the presence of mutations in the BRAF gene and the 
diagnosis of superficial spreading melanoma at an 
early age, located in the trunk and extremities and 
in an advanced tumor stage31. Although these 
results correspond only to ~ 20 % of the total 
sample, they coincide with the reports that 
approximately half of the patients with melanoma 
have some mutation in the BRAF gene, with the 
V600E mutation being the most frequent in younger 
patients (under 55 years of age)32, both at the time 
of diagnosis of primary melanoma and in the 
diagnosis of metastasis20. Jakob et al. reported that 
there is no association between the BRAF mutation 
and the Breslow depth index, the mitotic rate or the 
ulceration in melanoma, although the highest 
frequency of the mutation occurs in melanoma with 
superficial morphology, followed by nodular, lentigo 
maligna and lentiginous acral subtypes33,34. 
However, in this analysis (Table 2) the V600E BRAF 
mutation was identified only in patients with 
advanced disease, worsening the already poor 
prognosis by the lack of response to a specific 
antigen therapy35. 
 
As already pointed out in this study, it was not 
possible to carry out gene sequencing in all the D
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tumors of the sample, mainly due to the conditions 
in the fixation processes that seem to affect the 
molecular quality of paraffin-embedded samples. 
Different conditions such as pH, the nature of the 
fixative and its concentration can promote cross-
linking between nucleic acids and proteins in the 
material preserved in paraffin and formaldehyde, 
hindering the extraction of DNA and inhibiting 
PCR36,38.  
 
The five-year survival rate in patients diagnosed 
with malignant melanoma in the sample analyzed is 
40 %, lower than that reported by the National 
Cancer Institute of Colombia (54 %)39; in other Latin 
American and Asian studies, values are very close40-
42. The probability of survival in Colombia is low 
compared to the United States (82.6 %) and some 
European countries (France 76.0 % and Germany 
82.0 %)43-45 where incidence is higher. This low 
probability of survival is because, in Colombia and 
Latin American countries, the disease is diagnosed 
in an advanced state, highly increasing the 
probability of death from 7.4 % in no metastatic 
state and small thickness, as reported in other 
countries, to our reported data of 60 %46,47, possibly 
due to the precarious access to the health system.  
 
Currently, a limiting factor in melanoma research in 
the country is the lack of information on incidence 
and mortality rates. The most complete registry 
available is that of GLOBOCAN in 2012; however, 
given that Colombia does not have a single 
population registry that allows unifying cases of 
melanoma at the national level, statistics are based 
on reports from the cities of Medellin and Pasto. 
Moreover, complete epidemiological data are not 
recorded, which made it difficult to determine the 
frequency with which melanoma occurs in the 
Ibague population. In conclusion, it could be stated 
that the lack of information coverage indicates that, 
in works such as those carried out in Cali, the INC 
and even the present study, the actual magnitude of 
melanoma may be underestimated16,24. This work 
opens the door to other studies that may generate 
early detections for this type of skin cancer, 
reported as the most aggressive, and encourage 
prevention campaigns that help increase early 
prognosis and prevent and reduce the development 
of the pathology. 
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